Search Results - Jeffrey A. Engelman

Refine Results
  1. 1
    <i>ALK</i> in Lung Cancer: Past, Present, and Future

    <i>ALK</i> in Lung Cancer: Past, Present, and Future by Alice T. Shaw, Jeffrey A. Engelman

    Published 2013
    Get full text
    Revisão
    Save to List
    Saved in:
  2. 2
    SnapShot: Non-Small Cell Lung Cancer

    SnapShot: Non-Small Cell Lung Cancer by Rebecca S. Heist, Jeffrey A. Engelman

    Published 2012
    Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics

    ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics by Carlos L. Arteaga, Jeffrey A. Engelman

    Published 2014
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  4. 4
    The Role of the ErbB Family Members in Non–Small Cell Lung Cancers Sensitive to Epidermal Growth Factor Receptor Kinase Inhibitors

    The Role of the ErbB Family Members in Non–Small Cell Lung Cancers Sensitive to Epidermal Growth Factor Receptor Kinase Inhibitors by Jeffrey A. Engelman, Lewis C. Cantley

    Published 2006
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  5. 5
    Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer

    Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer by Jeffrey A. Engelman, Pasi A. Jänne

    Published 2008
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  6. 6
    Chemoprevention Meets Glucose Control

    Chemoprevention Meets Glucose Control by Jeffrey A. Engelman, Lewis C. Cantley

    Published 2010
    Get full text
    Carta
    Save to List
    Saved in:
  7. 7
    Bypass Mechanisms of Resistance to Receptor Tyrosine Kinase Inhibition in Lung Cancer

    Bypass Mechanisms of Resistance to Receptor Tyrosine Kinase Inhibition in Lung Cancer by Matthew J. Niederst, Jeffrey A. Engelman

    Published 2013
    Get full text
    Revisão
    Save to List
    Saved in:
  8. 8
    Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers

    Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers by Ryan B. Corcoran, Jeffrey Settleman, Jeffrey A. Engelman

    Published 2011
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  9. 9
    Genetic Changes in Squamous Cell Lung Cancer: A Review

    Genetic Changes in Squamous Cell Lung Cancer: A Review by Rebecca S. Heist, Lecia V. Sequist, Jeffrey A. Engelman

    Published 2012
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  10. 10
    The PI3K Pathway As Drug Target in Human Cancer

    The PI3K Pathway As Drug Target in Human Cancer by Kevin D. Courtney, Ryan B. Corcoran, Jeffrey A. Engelman

    Published 2010
    Get full text
    Revisão
    Save to List
    Saved in:
  11. 11
    Specific Inhibitors of p38 Mitogen-activated Protein Kinase Block 3T3-L1 Adipogenesis

    Specific Inhibitors of p38 Mitogen-activated Protein Kinase Block 3T3-L1 Adipogenesis by Jeffrey A. Engelman, Michael P. Lisanti, Philipp E. Scherer

    Published 1998
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  12. 12
    The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics

    The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics by Aaron N. Hata, Jeffrey A. Engelman, Anthony C. Faber

    Published 2015
    Get full text
    Revisão
    Save to List
    Saved in:
  13. 13
    Overcoming resistance to tyrosine kinase inhibitors: Lessons learned from cancer cells treated with EGFR antagonists

    Overcoming resistance to tyrosine kinase inhibitors: Lessons learned from cancer cells treated with EGFR antagonists by Brent N. Rexer, Jeffrey A. Engelman, Carlos L. Arteaga

    Published 2009
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  14. 14
    Targeting the PI3K signaling pathway in cancer

    Targeting the PI3K signaling pathway in cancer by Kwok‐Kin Wong, Jeffrey A. Engelman, Lewis C. Cantley

    Published 2009
    Get full text
    Revisão
    Save to List
    Saved in:
  15. 15
    Genes encoding human caveolin‐1 and ‐2 are co‐localized to the D7S522 locus (7q31.1), a known fragile site (FRA7G) that is frequently deleted in human cancers

    Genes encoding human caveolin‐1 and ‐2 are co‐localized to the D7S522 locus (7q31.1), a known fragile site (FRA7G) that is frequently deleted in human cancers by Jeffrey A. Engelman, Xiao Lan Zhang, Michael P. Lisanti

    Published 1998
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  16. 16
    The present and future of PI3K inhibitors for cancer therapy

    The present and future of PI3K inhibitors for cancer therapy by Pau Castel, Eneda Toska, Jeffrey A. Engelman, Maurizio Scaltriti

    Published 2021
    Get full text
    Artigo
    Save to List
    Saved in:
  17. 17
    Tyrosine kinase gene rearrangements in epithelial malignancies

    Tyrosine kinase gene rearrangements in epithelial malignancies by Alice T. Shaw, Peggy P. Hsu, Mark M. Awad, Jeffrey A. Engelman

    Published 2013
    Get full text
    Revisão
    Save to List
    Saved in:
  18. 18
    Chromosomal localization, genomic organization, and developmental expression of the murine caveolin gene family (Cav‐1, ‐2, and ‐3)

    Chromosomal localization, genomic organization, and developmental expression of the murine caveolin gene family (Cav‐1, ‐2, and ‐3) by Jeffrey A. Engelman, Xiao Lan Zhang, Ferruccio Galbiati, Michael P. Lisanti

    Published 1998
    Get full text
    Artigo
    Save to List
    Saved in:
  19. 19
    Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin

    Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin by Matthew G. Oser, Matthew J. Niederst, Lecia V. Sequist, Jeffrey A. Engelman

    Published 2015
    Get full text
    Revisão
    Save to List
    Saved in:
  20. 20
    Targeted Down-regulation of Caveolin-3 Is Sufficient to Inhibit Myotube Formation in Differentiating C2C12 Myoblasts

    Targeted Down-regulation of Caveolin-3 Is Sufficient to Inhibit Myotube Formation in Differentiating C2C12 Myoblasts by Ferruccio Galbiati, Daniela Volonté, Jeffrey A. Engelman, Philipp E. Scherer, Michael P. Lisanti

    Published 1999
    Get full text Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: